RxDoctor Payments Data

Matthew Peters, PA

Medical · Augusta, GANPI 1043312572

Payments from drug & device makers

$3,030in general payments, 2019–2025

Across 123 payments — averaging $24.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$580
  • AstraZeneca$494
  • Travere Therapeutics, Inc.$276
  • Fresenius USA Marketing, Inc.$219
  • Aurinia Pharma U.S., Inc.$186
  • Ardelyx, Inc.$179
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$2,99799%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,030 in reported general payments places this provider in the 75th percentile of 950 medical providers in Georgia.

See all medical providers in Georgia

Medicare billing

Part B allowed, 2024
$17,680
Medicare patients
71
Services billed
239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl13$52,127
VelphoroSucroferric Oxyhydroxide16$44,692
AuryxiaFerric Citrate17$33,672
Sevelamer Carbonate75$10,389
Lanthanum Carbonate13$9,882
Hydroxyzine Hcl17$581
Albuterol Sulfate HfaAlbuterol Sulfate21$511
Cyproheptadine Hcl11$379
Gabapentin25$327
Ondansetron Hcl23$308
Calcitriol24$299
Carvedilol37$181
Hydralazine Hcl17$170
Allopurinol19$155
Furosemide34$128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$219$44,69216 claims
Akebia Therapeutics IncAuryxia$24$33,67217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 950 medical providers in Georgia.

Other medical in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →